Journals / Retina-Vitreus / 2012 / Cilt: 20 - Sayı: 2

The efficiency of vascular endothelial growth factor inhibitors in central serous chorioretinopathy cases

Akut santral seröz koryoretinopati olgularında, vasküler endotelyal büyüme faktörü inhibitör tedavisinin etkinliği

Pages
111–116
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: IVB injection was thought to cause rapid recovery of the clinical and FA findings with a decrease in the mean CMT and an increase in the mean VA values in acute CSR cases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To determine the effect of intravitreal bevacizumab (IVB) injection on visual acuity and central macular thickness (CMT) values in acute central serous chorioretinopathy (CSR) cases.
📊
Key Findings & Data:Materials and Methods: 30 eyes of 30 cases with acute CSR, who had undergone one injection of IVB between January 2009 and December 2011, were included to our retrospective study.
💡
Conclusion & Impact:Conclusion: IVB injection was thought to cause rapid recovery of the clinical and FA findings with a decrease in the mean CMT and an increase in the mean VA values in acute CSR cases.
🔬Design:Review & Systematic Survey
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Abstract

Purpose: To determine the effect of intravitreal bevacizumab (IVB) injection on visual acuity and central macular thickness (CMT) values in acute central serous chorioretinopathy (CSR) cases. Materials and Methods: 30 eyes of 30 cases with acute CSR, who had undergone one injection of IVB between January 2009 and December 2011, were included to our retrospective study. Medical records of the cases including best-corrected visual acuity (VA) with Snellen charts, anterior and posterior segment examinations, CMT values measured by optical coherence tomography (OCT) and fundus fluorescein angiography (FA) findings before and after IVB injections were reviewed. Paired-sample t tests were used for statistical analysis. Results: The mean VA before IVB was 0.73±0.11 (0.4-0.9), while it was 0.86±0.8 (0.7-1.0) at the first month, 0.90±0.9 (0.7-1.0) at the third and 0.89±12 (0.6-1.0) at the sixth month after treatment. The VA values after IVB were statistically significantly higher than the pre-treatment value (p=0.000). But no statistically significant difference was found between the VA values at the first and sixth month after treatment (p=0.109). The mean CMT value was 457.5±68.8 μm before treatment, while it was 318.2±55.8 at the first, 231.1±36.7 at the third and 220.6±63.2 μm at the sixth month after İVB injection. The differences between the mean values of CCT before and after the treatment were statistically significant (p=0.000). Conclusion: IVB injection was thought to cause rapid recovery of the clinical and FA findings with a decrease in the mean CMT and an increase in the mean VA values in acute CSR cases.

Özet

Amaç: Akut santral seröz koryoretinopati (SSKR) olgularında intravitreal bevacizumab’ın (İVB), merkezi makülar kalınlık (MMK) ve görme keskinliği (GK) üzerine olan etkisinin değerlendirilmesi. Gereç ve Yöntem: Ocak 2009-Aralık 2011 tarihleri arasında akut SSKR nedeni ile bir defa İVB enjeksiyonu yapılan 30 olgunun 30 gözü çalışma kapsamına alındı. Hastaların tedavi öncesi ve tedavi sonrasında Snellen eşeli ile düzeltilmiş görme keskinlikleri (GK), ön ve arka segment muayeneleri, optik kohorens tomografi (OKT) ile ölçülen MMK değerleri ve fundus flöresein anjiografi (FA) görüntülemeleri, geriye dönük olarak incelendi. İstatistiksel analizlerde bağımlı gruplarda t test kullanıldı. Bulgular: İVB öncesi ortalama GK değeri 0.73±0.11 (0.4-0.9) iken, İVB sonrası 1. ayda 0.86±0.8 (0.7-1.0), 3. ayda 0.90±0.9 (0.7- 1.0) ve 6. ayda 0.89±12 (0.6-1.0) olarak saptandı. Tedavi sonrası birinci, üçüncü ve altıncı aydaki GK değerleri, enjeksiyon öncesi değerlere göre anlamlı ölçüde yüksekti (p=0.000). Ancak tedavi sonrası değerler karşılaştırıldığında, İVB sonrası 1. ve 6. aydaki GK değerleri arasında istatistiksel olarak anlamlı fark yoktu (p=0,109). IVB öncesi ortalama MMK değeri 457.5±68.8 μm iken, tedavi sonrası 1. ayda 318.2±55.8 μm, 3. ayda 231.1±36.7 μm ve 6. ayda ise 220.6±63.2 μm olarak saptandı. Tedavi öncesi ve sonrası MMK değerleri arasındaki farklar, istatistiksel olarak anlamlı bulundu (p=0.000). Sonuç: Akut SSKR olgularında İVB tedavisinin, FA ve klinik bulgularda hızlı bir düzelmeye sebep olarak MMK değerlerinde azalmaya ve GK değerlerinde artışa sebep olduğu sonucuna gidildi.

🔖

Cite This Article

TEKE, M. Y., ŞEN, E., ELGİN, K. U., ÖZDAL, M. P. Ç., ÖZTÜRK, F. (2012). The efficiency of vascular endothelial growth factor inhibitors in central serous chorioretinopathy cases. Retina-Vitreus, Cilt: 20 - Sayı: 2, 111–116. https://ajindex.com/articles/308065

References (15)

  1. Von Graefe A. Ueber centrale recidivirente retinitis. Alberecht von Graefes. Arch Ophthalmol.1866;12:211-5
  2. Gäckle HC, Lang GE, Freisser KA, et al. Central serous chorioretinopathy. Clinical, fluorescein angiography and demographic aspects. Ophthalmologe. 1998;95:529-33
  3. Tunçay FY, Gürelik G. Santral seröz koryoretinopati. Ret-Vit 2010,18:85-111 4. Wang M, Munch IC. Central serous chorioretinopathy. Acta Opthalmol 2008;86:126-45
  4. Wang MS, Sander B, Larsen M. Retinal atrophy in idiopathic central serous chorioretinopathy. Am J Ophthalmol 2002;133:787-93
  5. Guyer DR, Yannuzzi LA, Slakter JS, et al. Digital indocyanin green videoangiography of the central serous chorioretinopathy. Arch Ophthalmol 1994;112:1057-62
  6. Stanga PE, Lim JI, Hamilton P. Indocyanine green angiography in chorioretinal diseases: indications and interpretation: an evidence-based update. Ophthalmology 2003;110:15-21
  7. Atmaca LS, Batıoğlu F, Atmaca P. Santral seröz korioretinopatide floresein ve indosiyanin green videoanjiografi. MN Oftalmol 1988;5:195-8 9. Bujarborua D. Long term follow up of idiopathic central serous chorioretinopathy without laser. Acta Ophthalmol Scand 2001;79:417-21
  8. Loo RH, Scott IU, Flynn HW Jr, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 2002;22:19-24
  9. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to agerelated macular degeneration. Retina 2006;26:383-90
  10. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.Retina 2006;26:495-511
  11. Friedlander SM, Welch RM. Vanishing disc neovascularization following intravitreal bevacizumab (avastin) injection. Arch Ophthalmol 2006;124:1365
  12. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26:279-84
  13. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007;91:161-5
  14. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2006;37:144-6
  15. Huang WC, Chen WL, Tsai YY, et al. Intravitreal bevacizumab for treatmen